-
Cancer Drug Response: Better In Vitro Interpretation
2026-09-08
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but not interchangeable drug-response outcomes. This framework can improve assay interpretation, time-course design, and translational evaluation in cancer research.
-
CP-673451: Selective PDGFRα/β Inhibitor Workflow
2026-09-08
CP-673451 enables a linked workflow from PDGFR target engagement and angiogenesis inhibition assay design to ATRX-stratified glioma studies. Its strong PDGFRα/β preference makes it useful for separating PDGFR biology from broader RTK effects in cancer research.
-
Alternariol Workflows for Fibrosis Research
2026-09-07
Use Alternariol (AOH) as a controlled tool for connecting mycotoxin exposure with hepatic stellate cell activation, apoptosis, and metabolic transformation. This workflow combines practical dosing, orthogonal phenotyping, Cytochrome P450 enzyme assays, and troubleshooting strategies for reproducible mechanistic studies.
-
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-09-07
Masitinib (AB1010), SKU A2942, is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for research on KIT, PDGFRα, PDGFRβ, mast-cell responses, and related cancer models. It is appropriate for controlled biochemical and cellular assays, but not for aqueous or ethanol-based protocols, broad-spectrum kinase screening, or clinical dosing decisions.
-
Sulfo-NHS-SS-Biotin for Reliable Cell Assays
2026-09-05
Learn how Sulfo-NHS-SS-Biotin (SKU A8005) supports reproducible cell-surface protein labeling alongside viability, proliferation, and cytotoxicity workflows. This scenario-based guide explains reagent chemistry, compatibility, protocol control, data interpretation, and practical product-selection criteria.
-
SB525334 TGF-beta1 Receptor Inhibitor Workflows
2026-09-04
Learn how to use SB525334 to test ALK5-dependent Smad signaling in fibrosis, renal disease, and wound-healing models. The workflow emphasizes pathway-specific controls, orthogonal readouts, and careful interpretation of TGF-β1 inhibition in diabetic wound research.
-
HRD1-SEL1L Controls Stress Granule Homeostasis
2026-09-04
Shi and colleagues identify the HRD1-SEL1L ubiquitin ligase as a regulator of heat shock-induced stress granule homeostasis and connect this activity to the BiP-PERK-eIF2α branch of endoplasmic reticulum stress. The study provides a mechanistic framework for examining how ubiquitin-proteasome function, p97 activity, and stress granule dynamics cooperate during proteotoxic stress.
-
Dinaciclib Selectively Targets VHL-Deficient CC-RCC
2026-09-03
The reference study identifies a synthetic-lethal relationship between Dinaciclib treatment and loss of the VHL tumor suppressor in clear cell renal cell carcinoma. Its combination of cell-based, mechanistic, and orthotopic patient-derived xenograft experiments suggests that cell-cycle inhibition can suppress both CD105-positive and CD105-negative tumor populations while retaining a context-dependent therapeutic window.
-
NHS-Biotin Workflows for Protein Assembly
2026-09-03
NHS-Biotin connects amine-reactive chemistry with sensitive streptavidin-based detection, purification, and intracellular labeling workflows. This guide shows how to label antibodies, proteins, and engineered nanobody assemblies while controlling hydrolysis, steric effects, background, and cell compatibility.
-
Recombinant Mouse SHH for Morphogen Assays
2026-09-02
Explore how Recombinant Mouse Sonic Hedgehog can convert comparative embryology into controlled morphogen assays. This guide connects SHH protein handling, alkaline phosphatase induction, and recent mouse–guinea pig findings to better experimental decisions in developmental biology.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-02
AZD8055 (SKU A8214) is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling in cellular and animal models. It is best suited to preclinical mechanism and pathway experiments, not protocols centered on aqueous formulation, long-term solution storage, or clinical efficacy endpoints.
-
Dorsomorphin 2HCl: AMPK Workflow
2026-09-01
Dorsomorphin 2HCl enables controlled AMPK inhibition in hepatic lipid-metabolism studies while also providing a useful perturbation tool for BMP, osteogenesis, and hepcidin research. This practical workflow emphasizes solvent control, pathway-specific readouts, and careful interpretation of its dual AMPK–BMP activity.
-
Virus Flexibility for Rare-Cell Cancer Subtyping
2026-09-01
The reference study shows that mechanically flexible M13 bacteriophage nanofibers can improve circulating tumor cell capture while limiting nonspecific white blood cell adsorption. By combining selective isolation with immunostaining, the platform supports breast cancer discrimination and subtype assignment, while also highlighting how nanoscale mechanics can complement ligand design.
-
Itraconazole Workflows for Candida Biofilm Studies
2026-08-31
Build reproducible Candida biofilm assays with Itraconazole while separating direct antifungal activity from PP2A- and autophagy-linked drug tolerance. The workflow also supports antifungal drug interaction studies, CYP3A4 investigations, and carefully bounded translational models.
-
Sulfo-NHS-SS-Biotin for Surface Protein Workflows
2026-08-31
Sulfo-NHS-SS-Biotin enables water-compatible labeling of primary amines, selective cell-surface capture, and reversible affinity enrichment. Its cleavable disulfide spacer is especially useful for distinguishing internalized proteins from surface-retained populations and for validating spatial trafficking models such as the Notch receptor network.